BioMarin Pharmaceutical Inc. — Form 8-K Summary
Business context and reporting period
BioMarin reported entering into a Settlement and License Agreement with Ascendis Pharma A/S on September 24, 2026. The agreement is deemed effective August 28, 2026, and supersedes the binding term sheet previously reported on August 31, 2026. The 8-K was signed September 30, 2026.
Key financial terms
- Ascendis will pay BioMarin royalties on annual net sales of licensed products: 20% in the United States and 18% in the European Union, Brazil, and South Korea.
- Royalties apply from the first commercial sale in each territory, retroactively where applicable, through May 2030.
- The filing gives no current sales, royalty receipts, financial-statement metrics, or estimate of future royalty amounts.
Agreement terms and changes
- BioMarin granted Ascendis and its affiliates a non-exclusive, worldwide, transferable, royalty-bearing license to specified BioMarin patents covering TransCon CNP, navepegritide, or Yuviwel, for all current and potential indications, including achondroplasia and hypochondroplasia, and use in combination with other medicines.
- The parties will dismiss with prejudice all pending litigation between them relating to the licensed patent rights. The agreement’s terms are described as consistent with the previously reported term sheet, which it replaces.
- The agreement also includes mutual regulatory non-interference, Ascendis’s covenant not to challenge the patent rights, and BioMarin’s release of certain pre-effective-date infringement claims and covenant not to sue Ascendis for infringement of those rights.
Outlook, risks, and contingencies
BioMarin identifies anticipated royalty payments, future commercialization, and dismissal of the legal proceedings as forward-looking matters, not assured outcomes. Cited risks include the parties’ ability to enforce the agreement and actual licensed-product sales. The filing provides no quantified sales or royalty forecast.
Important facts for investors to verify
- Whether and when pending litigation is dismissed with prejudice.
- Licensed-product commercialization and net sales by territory, which determine royalty payments.
- Whether the agreement is enforceable and royalties are paid as provided through May 2030.
- Relevant risk disclosures in BioMarin’s Form 10-Q for the quarter ended June 30, 2026, and subsequent filings.